Format

Send to

Choose Destination
Science. 2018 Mar 23;359(6382):1361-1365. doi: 10.1126/science.aar6711.

CAR T cell immunotherapy for human cancer.

Author information

1
Center for Cellular Immunotherapies, Perlman School of Medicine, Philadelphia, PA, USA. cjune@exchange.upenn.edu.
2
Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA, USA.
3
Department of Pathology and Laboratory Medicine, Perlman School of Medicine, Philadelphia, PA, USA.
4
Center for Cellular Immunotherapies, Perlman School of Medicine, Philadelphia, PA, USA.

Abstract

Adoptive T cell transfer (ACT) is a new area of transfusion medicine involving the infusion of lymphocytes to mediate antitumor, antiviral, or anti-inflammatory effects. The field has rapidly advanced from a promising form of immuno-oncology in preclinical models to the recent commercial approvals of chimeric antigen receptor (CAR) T cells to treat leukemia and lymphoma. This Review describes opportunities and challenges for entering mainstream oncology that presently face the CAR T field, with a focus on the challenges that have emerged over the past several years.

PMID:
29567707
DOI:
10.1126/science.aar6711
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center